Cizzle presents at SYNLAB Innovation Symposium

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to highlight further industry engagement and the Company’s participation at a leading NHS partner’s symposium

Highlights

Cizzle Biotechnology is participating in the SYNLAB 12th Innovation Academy Symposium on 5 November 2026

Co-presentation at the symposium of technical evaluation studies of the Company’s CIZ1B biomarker test underway at the Christie Pathology Partnership, Manchester

Communication of test improvements, as reported in peer-reviewed publication ‘The Journal of Applied Laboratory Medicine’

Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said

“I am delighted that Cizzle has been invited to present its latest improvements to the CIZ1B test to such a knowledgeable audience. The progress we have made this year has enabled precise and reproducible measurement of the CIZ1B lung cancer biomarker, using scalable reagents that will be the foundation of a future high-throughput test kit.”

The Company maintains a research and collaboration agreement with the University of York which supports the development of CIZ1B biomarker test improvements, and independent validation as a clinical assay for early-stage lung cancer.

Technical progress arising from the collaboration was recently reported in ‘A Molecular Tool Set for Measurement of Lung Cancer-Associated Protein Biomarker CIZ1B-FibA in Human Plasma’ Susanna F Rose, Joanna F Pearson, Lewis Byrom, Justin F X Ainscough, Dawn Coverley The Journal of Applied Laboratory Medicine. The paper, which may be accessed via: https://doi.org/10.1093/jalm/jfag124, evidences accuracy and reproducibility standards for the CIZ1B biomarker test that meet those required by major healthcare service providers.

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

About SYNLAB UK & Ireland

SYNLAB UK & Ireland delivers high‑quality laboratory and diagnostic services, performing more than 65 million tests every year, from routine blood tests to advanced molecular and genetic analysis. With a team of more than 3,000 people it supports NHS and private user through four NHS services; The Christie Pathology Partnership in Manchester, SYNLA Essex, Southwest Pathology Services in Somerset, and Synnovis, its partnership with Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.

The Christie Pathology partnership (CPP) is a joint venture between SYNLAB UK & Ireland and The Christie NHS Foundation Trust in Manchester. The partnership was established in June 2014, and renewed in May 2025. It will see significant invest from SYNLAB into new state-of-the-art laboratories for increased capacity, resilience, and research funding. CPP is UKAS Accredited and delivers specialist oncology and clinical pathology diagnostics to the NHS, and the private pay market, serving a population of about 3.2 million people in and around Manchester.